Bayer Net Change in Short-term Investments 2010-2025 | BAYRY

Bayer annual/quarterly net change in short-term investments history and growth rate from 2010 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
  • Bayer net change in short-term investments for the quarter ending March 31, 2025 was $0.740B, a 0% increase year-over-year.
  • Bayer net change in short-term investments for the twelve months ending March 31, 2025 was $6.482B, a 18.54% increase year-over-year.
  • Bayer annual net change in short-term investments for 2024 was $2.768B, a 2363.3% decline from 2023.
  • Bayer annual net change in short-term investments for 2023 was $-0.122B, a 93.65% decline from 2022.
  • Bayer annual net change in short-term investments for 2022 was $-1.926B, a 138.17% decline from 2021.
Bayer Annual Net Change in Short-term Investments
(Millions of US $)
2024 $2,768
2023 $-122
2022 $-1,926
2021 $5,046
2020 $-280
2019 $-339
2018 $3,352
2017 $1,744
2016 $-6,247
2015 $-382
2014 $-222
2013 $129
2012 $1,709
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $32.616B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $696.621B 45.58
Johnson & Johnson (JNJ) United States $425.048B 17.65
AbbVie (ABBV) United States $368.080B 19.67
Novartis AG (NVS) Switzerland $267.517B 14.49
Roche Holding AG (RHHBY) Switzerland $256.819B 0.00
Novo Nordisk (NVO) Denmark $247.093B 14.96
Merck (MRK) United States $212.287B 11.12
Pfizer (PFE) United States $141.684B 7.35
Sanofi (SNY) France $123.512B 12.24
Innoviva (INVA) United States $1.256B 12.38